A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).

Eur Heart J Cardiovasc Imaging · 2015 · PMC4505792 · PMID 25796267

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Potential effect on the aortic valve The ramipril group showed a trend towards reduced progression of the AS (change in valve area 0 vs. −0.2 cm 2 in the ramipril and placebo groups respectively, though the statistical strength of the difference was weak ( P = 0.067).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.